Kane Biotech Inc. filed its Annual on Apr 08, 2013 for the period ending Dec 31, 2012. In this report its auditor, Meyers Norris Penny LLP - MNP LLP, gave an unqualified opinion expressing doubt that the company can continue as a going concern.

Kane Biotech Inc. announced that the DispersinB-Gentamicin combination wound gel spray has passed the primary skin irritation tests. The purpose of the skin irritation test is to determine the dermal irritation potential of topical DispersinB-Gentamicin wound gel spray as required by the FDA for biocompatibility. The biocompatibility study was conducted on the combination of DispersinB antibiofilm enzyme and the broad-spectrum antibiotic Gentamicin. The study was conducted in compliance with Good Laboratory Practices (GLP) and also in accordance with the International Organization of Standardization: Biological Evaluation of Medical Devices, Part 10: Test for Irritation and Sensitization. Based on the skin irritation index (PII) for the formulation, the irritation response was negligible, thus the DispersinB-Gentamicin wound gel spray does not cause dermal erythema or edema due to skin irritation. Kane Biotech has two DispersinB-based wound gel spray formulations in development for the topical wound care market. The first product is the DispersinB-Gentamicin wound gel spray for topical wound care in both human and veterinary applications. DispersinB-antimicrobial combinations have shown to be effective against Methicillin-Resistant Staphylococcus Aureus (MRSA) and Methicillin-resistant Staphylococcus pseudintermedius (MRSP) associated with human and companion animal wound infections, respectively. The second wound care product is in collaborative development with the US Army Institute of Surgical Research for combat wound infections.

Kane Biotech Inc. will launch its marketing field test for StrixNB, its revolutionary new pet oral care product, in Manitoba on February 1, 2013 in conjunction with Pet Dental Health Month. Kane Biotech is a biotechnology company engaged in the development and commercialization of products that prevent and remove microbial biofilms. Manitoba pet owners will be the first in Canada to have access to this easy-to-use companion animal oral care product that has the potential to change the way one care for ones pets' teeth. StrixNB is a new, safe and effective drinking water additive scientifically formulated to help maintain and promote good dental and oral hygiene in pets. It is unique because it works against bacteria associated with dental disease by altering the mouth's environment. It breaks through dental biofilm - a highly structured, matrix-embedded microbial population - making bacteria accessible for eradication by a microbial agent. StrixNB is made using a unique formulation of food grade ingredients and has received a notification number NN.1Q11 from the Interim Notification Program of Health Canada for Low Risk Veterinary Health Products. It is safe for everyday consumption and works for all breeds and sizes of dogs.